* Protara Therapeutics Inc TARA.OQ reported a quarterly
adjusted
loss of 80 cents per share for the quarter ended in March. The
mean expectation of three analysts for the quarter was for a
loss of 88 cents per share.
* Reported revenue was zero; analysts expected zero.
* Protara Therapeutics Inc's reported EPS for the quarter
was a
loss of 80 cents.
* The mean earnings estimate of analysts had fallen by
about 5.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* Protara Therapeutics Inc shares had fallen by 1.3% this
quarter and gained 15.3% so far this year.
* The company reported a quarterly loss of $9.05 million.
* Wall Street's median 12-month price target for Protara
Therapeutics Inc is $31.00
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data May
4 at 05:50 p.m. UTC. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2023 -0.88 -0.80 Beat
Dec. 31 2022 -0.75 -1.55 Missed
Sep. 30 2022 -0.76 -0.68 Beat
Jun. 30 2022 -0.94 -0.80 Beat